|Bid||10.00 x 1400|
|Ask||16.16 x 900|
|Day's Range||13.71 - 14.44|
|52 Week Range||13.66 - 21.86|
|Beta (5Y Monthly)||0.45|
|PE Ratio (TTM)||23.65|
|Earnings Date||Feb 08, 2022 - Feb 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.00|
San Diego, CA, based Investment company Denali Advisors Llc (Current Portfolio) buys Sanmina Corp, Mueller Industries Inc, BlueLinx Holdings Inc, Triton International, World Fuel Services Corp, sells , Adtalem Global Education Inc, Tegna Inc, Federal Agricultural Mortgage Corp, AdvanSix Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Denali Advisors Llc.
Bethesda, MD, based Investment company Profit Investment Management, LLC (Current Portfolio) buys Patterson Inc, Vanda Pharmaceuticals Inc, Plantronics Inc, American Equity Investment Life Holding Co, PetMed Express Inc, sells , WESCO International Inc, Southwest Airlines Co, Mastercard Inc, NortonLifeLock Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Profit Investment Management, LLC.
D.C.’s Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has settled a patent infringement lawsuit with a generic competitor over the local company’s key product. Vanda said Friday it has inked a license deal that puts to bed litigation against Piscataway, New Jersey’s MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd., which wanted to make a generic version of Hetlioz, Vanda’s treatment for non-24-hour sleep-wake disorder. The agreement gives a nonexclusive license to MSN and Impax Laboratories LLC of Hayward, Connecticut (part of Bridgewater, New Jersey’s Amneal Pharmaceuticals LLC), to make and commercialize a product using tasimelteon — the active ingredient in Hetlioz — starting March 13, 2035.